Nalador 500 (Sulprostone)

Sulprostone, the active ingredient in Nalador 500, is a prostaglandin E2 analog presented as an injectable solution for intravenous use. It is employed to stimulate uterine contractility for labor induction, to manage postpartum hemorrhage, and to aid in the prevention of recurrent gastric ulcers.

GNH USA supplies Nalador 500 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, adhering to stringent quality standards and providing reliable logistics for global distribution.

Sulprostone is used in obstetric and gastrointestinal settings where prostaglandin‑mediated uterine activity or gastric protection is required. - Induction of labor: facilitates cervical ripening and uterine contractions to initiate delivery. - Management of postpartum hemorrhage: enhances uterine tone to reduce bleeding after childbirth. - Prevention of gastric ulcer recurrence: promotes mucosal protection and reduces ulcer re‑formation.

Sulprostone may be associated with a range of adverse reactions, which are categorized by frequency. Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes. - Diarrhea: loose stools. - Flushing: transient skin redness. Serious or Rare Side Effects: - Severe uterine hyperstimulation: excessive contractions that may compromise fetal oxygenation. - Pulmonary edema: fluid accumulation in the lungs requiring medical attention. - Anaphylactic reaction: rapid onset of allergic symptoms such as airway swelling and hypotension.

When using Nalador 500, clinicians should observe several safety measures. - Contraindication in known hypersensitivity: avoid use in patients with documented allergy to sulprostone or related prostaglandins. - Caution in cardiovascular disease: monitor for hypertension or arrhythmias during infusion. - Use with care in asthma: prostaglandins may provoke bronchospasm. - Avoid in active labor with fetal distress: excessive uterine activity can worsen fetal condition. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sulprostone can interact with other medicines, requiring attention to potential effects. Major Interactions (Avoid): - Concurrent use with other uterotonics (e.g., oxytocin, misoprostol): may cause dangerous uterine hyperstimulation. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can diminish prostaglandin efficacy and increase bleeding risk. Moderate Interactions (Monitor Closely): - Antihypertensive agents: sulprostone may counteract blood pressure control; monitor hemodynamics. - Diuretics: potential for fluid imbalance when pulmonary edema risk is present. - Anticoagulants: increased bleeding tendency during postpartum hemorrhage management; observe coagulation parameters.